Aspira Women’s Health Inc. Announcement New York State Medicaid Now Considers OVA1® Medically Necessary as of April 1, 2021

Rhea-AI Summary

Aspira Women’s Health Inc. (Nasdaq: AWH) announced its subsidiary, Aspira Labs, has achieved credentialing with New York State’s Medicaid program, covering an estimated 6.5 million lives starting April 1, 2021. This credentialing expands the total covered lives for Aspira's OVA1® test to 179 million nationwide, enhancing access for ovarian cancer risk assessment. Aspira Labs is now credentialed in the top 9 U.S. states by Medicaid population, totaling nearly 60 million lives. The company aims to address health disparities in ovarian cancer risk detection.

Positive

• Credentialing with New York Medicaid adds 6.5 million covered lives, increasing total coverage for OVA1® testing to 179 million.
• Aspira Labs is now credentialed in the top 9 states by Medicaid population, expanding its market presence significantly.
• Positive coverage for OVA1® supports potential follow-on contracts in New York, enhancing commercial opportunities.

Negative

• None.

Second Largest Medicaid population in the U.S.

AUSTIN, Texas, March 15, 2021 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (Nasdaq: AWH), today announced its wholly owned subsidiary, Aspira Labs, is now credentialed with New York State’s Medicaid program for an estimated additional 6.5 million Medicaid lives. NY State Medicaid will begin to cover Aspira’s OVA1® test effective April 1, 2021.

New York has the second largest state Medicaid population in the U.S. and Aspira Labs is now credentialed in the top 9 states by Medicaid population size, including California, Florida, Illinois, Pennsylvania, Texas, and now New York. The addition of New York brings Aspira Labs’ total credentialed Medicaid population to almost 60 M Medicaid lives, which is over 78% of the U.S. Medicaid population. Aspira Labs is the only U.S. provider for Aspira’s proprietary OVA1® test, an FDA-cleared, ACOG recommended, and CMS supported ovarian cancer risk assessment for women with a pelvic mass.

The addition of 6.5M NY State Medicaid lives will also increase the total coverage for OVA1® testing to 179M nationwide. Positive coverage for OVA1®, combined with credentialing for Aspira Labs, opens up opportunities for follow-on commercial Medicaid contracts in NY State, especially when combined with peer-reviewed published evidence documenting OVA1®’s early detection and negative predictive value performance over CA125, and its marked performance in Black women as compared to CA125.

“Adding New York Medicaid coverage provides a large population of patients access to OVA1® and continues our mission to remove barriers for ALL women,” said Valerie Palmieri, President and CEO of Aspira Women’s Health, Inc. “Adding additional Medicaid states is a key cornerstone to our resolution of the health disparities in Ovarian Cancer risk detection. We are pleased to announce Aspira’s enrollment as a participating provider with State of New York Medicaid.”

About Aspira Women’s Health Inc.
Aspira Women’s Health Inc. (formerly known as Vermillion, Inc., Nasdaq: VRML) is transforming women’s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women. Aspira Women’s Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1® plus includes our FDA-cleared products, OVA1® and OVERA®, to detect risk of ovarian malignancy in women with adnexal masses. ASPIRA GenetiX^TM testing offers both targeted and more comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, Aspira Women’s Health is delivering a portfolio of pelvic mass products over a patient’s lifetime with our cutting-edge research. The next generation of products in development are OVASight^TM and EndoCheck^TM. Visit our website for more information at www.aspirawh.com.

Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
Tel 617-430-7577
Arr@lifesciadvisors.com

FAQ

What recent Medicaid credentialing did Aspira Women’s Health Inc. achieve?

Aspira Women’s Health Inc. announced credentialing with New York State Medicaid, covering an additional 6.5 million lives.

How many total lives does Aspira's OVA1® test cover after the new Medicaid expansion?

After the New York Medicaid expansion, total coverage for Aspira's OVA1® test reaches 179 million lives nationwide.

What is the significance of Aspira's credentialing in New York?

Credentialing in New York enhances access to ovarian cancer risk assessment for a large patient population and solidifies Aspira's position in the Medicaid market.

Which states does Aspira Labs serve with Medicaid credentialing?

Aspira Labs is now credentialed in nine states, including New York, California, Florida, Illinois, Pennsylvania, and Texas.